701 McMillian Way NW Ste F Rm 141 Huntsville, AL, 35806 United StatesAdvanced cellular intelligence for cell culture, culture media, reagent design, and process optimization. Multi-omic characterization plus biological digital twins delivering 2-9X improvements in titer, viability, and productivity — in as little as 1 week. Auperon is the productized cellular intelligence service from Van Heron Labs, Inc. (VHL), founded in 2020 and headquartered at the HudsonAlpha Institute for Biotechnology. VHL's platform combines in-silico multi-omic characterization with a proprietary biological digital twin to profile cells at mechanism-level depth — inferring the full molecular universe cells require, from trace metal cofactors through growth factors and chaperone systems, without depending on mass spectrometry detection or manual metabolic network annotation. Auperon delivers this capability as scoped, turnkey engagements with fixed scope, fixed price, and rapid turnarounds in as little as 1 week: built for process development, CMC, R&D, and reagent development teams who need mechanism-backed cellular insight without launching a full co-development program. VHL is a formally SBA-certified Woman Owned Small Business (WOSB). Services cover the full CMC, cell line development, and reagent development value chain: cellular characterization, media design and optimization, feed strategy development, reagent and supplement design (including hPL formulations, serum replacements, cell-type-specific supplements, and chemically defined alternatives), culture process optimization, cell line development support, comparability packages, and mechanism-defensible root-cause analysis and correction recommendations for viability, titer, phenotype, senescence, product quality, aggregation, immunogenicity, and manufacturability issues. We work across CHO, HEK, iPSC, MSC, T cells, Treg, TIL, and microbial systems — supporting monoclonal antibodies, bispecifics, ADCs, recombinant proteins, biosimilars, cell therapies, novel modalities, and next-generation culture reagents. Since 2020, VHL has completed nearly 30 engagements across pharma, biotech, CDMOs, and reagent/tools manufacturers, with active and completed programs including MilliporeSigma, Evonik, Mabxience, Rooster Bio, CTMC, and Stemmatters, and active programs scaling to 2000-5000L commercial bioreactor validation. Backed by NVIDIA, Microsoft, and AWS. Proven quantitative outcomes across modalities: Bioprocessing and HEK — 40-200% proliferation gains, up to 900% cell density improvements, 360% higher protein titer at equivalent cell density, 2X margin improvements. Cell therapy (CD4/8, TIL, Treg, iPSC, MSC) — 80% viability improvement, 40% activation increase, reduced CD8 bias without exhaustion, FOXP3 stability for enhanced Treg potency, resolved pluripotency and stress pathways enabling 5-month faster clinical timelines. Microbial (E. coli, B. subtilis, P. aeruginosa) — 200-400% proliferation increases, 200-360% higher titer, fully defined bioreactor media. Economics — $25K-$60K saved per batch, $5-25M annual COGS savings for at-scale programs, $10-60M in new ARR unlocked for reagent partners without expanded manufacturing infrastructure. What differentiates Auperon: every recommendation traces back to specific cellular biology, giving process development, CMC, and product development teams a defensible basis for change control, regulatory comparability filings, and next-generation product portfolio expansion. How engagements work: (1) Scoping call to align on your cells, process, and business objectives — typically 30 minutes. (2) Sample capture per VHL-provided SOPs from your existing production runs; no wet-lab work required on your end beyond routine sample collection. (3) VHL manages sequencing coordination, extraction, library prep, and QC through our vendor network — you ship cell pellets, we handle the rest. (4) Multi-omics analysis and biological digital twin construction, delivered as interactive dashboards plus a written technical report with specific, mechanism-backed recommendations. (5) Optional bench validation support through our CRO partner network or handoff to your team for implementation. Standard engagements complete in 1-8 weeks depending on tier; all engagements begin with fixed-scope statement of work.